Related Experiment Video
Updated: Mar 15, 2026
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
Targeting interleukin-1 receptor-associated kinase 1 for human hepatocellular carcinoma
Ning Li1, Jinhua Jiang2,3, Jing Fu2
1State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China.
Background:
Interleukin-1 receptor associated kinase 1 (IRAK1), as a down-stream of toll-like receptor (TLR) signaling, plays important roles in series of malignancies. However, the role of IRAK1 in hepatocellular carcinoma (HCC) remains little known.
Methods:
In our study, reverse transcription-PCR (RT-PCR), Western Blot, and immunohistochemical staining were used to assess the mRNA and protein levels of IRAK1 in clinical samples and cell lines. Cell counting assay and flow cytometry were employed to analyze the effect of IRAK1 on cell cycle and apoptosis. Transwell assay was used to study the role of IRAK1 in cell migration. Moreover, subcutaneous xenograft tumor models predict the efficacy of targeting IRAK1 against HCC in vivo.
Results:
IRAK1 was over-expressed in HCC tissues and cell lines. Suppression of IRAK1 by small interference RNA (siRNA) or a pharmaceutical IRAK1/4 inhibitor impeded cell growth, induced apoptosis and lessened HCC xenograft tumor growth. Particularly, IRAK1/4 inhibitor treatment caused G1/S cell cycle arrest and apoptosis, confirming IRAK1 as a new therapeutic target for HCC.
Conclusion:
IRAK1 promotes cell proliferation and protects against apoptosis in HCC, and can be a novel target for HCC treatment.
Insights
Interleukin-1 receptor associated kinase 1 (IRAK1) promotes hepatocellular carcinoma (HCC) growth and survival. Targeting IRAK1 offers a promising new therapeutic strategy for treating HCC, as it inhibits proliferation and induces apoptosis.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- Interleukin-1 receptor associated kinase 1 (IRAK1) is a downstream mediator of toll-like receptor (TLR) signaling.
- IRAK1's role in hepatocellular carcinoma (HCC) pathogenesis is not well understood.
- IRAK1 is implicated in various malignancies, highlighting its potential significance in cancer.
Purpose of the Study:
- To investigate the role and therapeutic potential of IRAK1 in hepatocellular carcinoma (HCC).
- To determine IRAK1's impact on HCC cell proliferation, apoptosis, and migration.
- To evaluate IRAK1 as a novel therapeutic target for HCC treatment.
Main Methods:
- Assessed IRAK1 mRNA and protein expression using RT-PCR, Western Blot, and immunohistochemistry in HCC samples and cell lines.
- Analyzed the effects of IRAK1 manipulation on cell cycle and apoptosis via cell counting assays and flow cytometry.
- Investigated IRAK1's role in cell migration using Transwell assays and evaluated in vivo efficacy in HCC xenograft models.
Main Results:
- IRAK1 was significantly over-expressed in HCC tissues and cell lines.
- Suppression of IRAK1, via siRNA or an IRAK1/4 inhibitor, reduced HCC cell growth and xenograft tumor progression.
- IRAK1 inhibition induced apoptosis and G1/S cell cycle arrest in HCC cells.
Conclusions:
- IRAK1 promotes HCC cell proliferation and inhibits apoptosis.
- IRAK1 represents a novel and viable therapeutic target for hepatocellular carcinoma treatment.
- Targeting IRAK1 demonstrates significant potential for HCC therapy.
More Related Videos
11:08Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
Published on: February 14, 2025
12:24A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
Related Concept Videos
01:22PI3K/mTOR/AKT Signaling Pathway
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...